

Plerixafor and G-CSF Therapy

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	*Reimbursement Status
Is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma and multiple myeloma whose cells mobilise poorly	C85 C90	00536a	Hospital

**If the reimbursement status is not defined¹, the indication has yet to be assessed through the formal HSE reimbursement process.*

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Plerixafor is administered by subcutaneous injection 11 hours (+/- 1 hour) prior to initiation of each apheresis following 4 day pre-treatment with G-CSF
A total of up to 3 doses of plerixafor is recommended.

Day	Drug	Dose	Route	Cycle
1 onwards	G-CSF	10mcg/kg (round to nearest whole syringe)	sc	Given in the morning from Day 1 onwards until harvest complete
4 onwards	Plerixafor	^a 20mg	sc	Given in evening with initiation of apheresis on morning of day 5 (11 hours (+/- 1 hour) later). Continue to administer each night if required, until harvest complete. This should be to a maximum of 3 doses,

^aA flat dose of 20mg is recommended for patients weighing 65-83kg
A dose of 0.24mg/kg is recommended for patients weighing <65kg or > 83kg
The dose should not exceed 40mg/day
The weight used to calculate the dose of plerixafor should be obtained within 1 week before the first dose of plerixafor.
Plerixafor dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated.
Ideal body weight can be determined using the following equations

- male (kg): $50 + 2.3 \times ((\text{Height (cm)} \times 0.394) - 60)$
- female (kg): $45.5 + 2.3 \times ((\text{Height (cm)} \times 0.394) - 60)$

ELIGIBILITY:

- Indication as above

EXCLUSIONS:

- Hypersensitivity to plerixafor or any of the excipients

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Haematologist working in the area of haematological malignancies

NCCP Regimen: Plerixafor and G-CSF	Published: 23/11/2018 Review: 23/11/2020	Version number: 1
Tumour Group: Leukaemia/BMT NCCP Regimen Code: 00536	IHS: Dr Kamal Fadalla	Page 1 of 3

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

TESTS:

Baseline tests:

- FBC , renal and liver profile

Regular tests:

- FBC, renal and CD34 count daily

Disease monitoring:

Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.

Renal and Hepatic Impairment:

Table 1: Dose modification of plerixafor in renal and hepatic impairment

Renal Impairment		Hepatic Impairment
Cr Cl (ml/min)	Dose	No information available
20-50	Reduce dose by 1/3 to 0.16mg/kg	
< 20 or haemodialysis	insufficient clinical experience to make dose recommendations	
Based on increasing exposure with increasing body weight the dose should not exceed 27 mg/day if the creatinine clearance is lower than 50 ml/min		

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: Minimal (**Refer to local policy**).

PREMEDICATIONS: None

OTHER SUPPORTIVE CARE: No specific recommendations

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Haematological effects:** Administration of plerixafor in conjunction with G-CSF increases circulating leukocytes as well as haematopoietic stem cell populations. White blood cell counts should be monitored during plerixafor therapy. Clinical judgment should be exercised when administering plerixafor to patients with peripheral blood neutrophil counts above 50×10^9 /L. Thrombocytopenia is a known complication of apheresis and has been observed in patients receiving plerixafor. Platelet counts should be monitored in all patients receiving plerixafor and undergoing apheresis.
- **Allergic reactions:** Plerixafor has been uncommonly associated with potential systemic reactions related to subcutaneous injection such as urticaria, periorbital swelling, dyspnoea, or hypoxia Symptoms responded to treatments (e.g., antihistamines, corticosteroids, hydration or supplemental oxygen) or resolved spontaneously. Cases of anaphylactic reactions, including

NCCP Regimen: Plerixafor and G-CSF	Published: 23/11/2018 Review: 23/11/2020	Version number: 1
Tumour Group: Leukaemia/BMT NCCP Regimen Code: 00536	IHS: Dr Kamal Fadalla	Page 2 of 3

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

anaphylactic shock, have been reported from world-wide post-marketing experience. Appropriate precautions should be taken because of the potential for these reactions.

- **Spleen size:** The effect of plerixafor on spleen size in patients has not been specifically evaluated in clinical studies. Cases of splenic enlargement and/or rupture have been reported following the administration of plerixafor in conjunction with growth factor G-CSF. Individuals receiving plerixafor in conjunction with G-CSF who report left upper abdominal pain and/or scapular or shoulder pain should be evaluated for splenic integrity.
- Other adverse effects include gastrointestinal symptoms such as nausea, flatulence and vomiting, headache, arthralgia, dizziness and insomnia (patients should be advised against driving).

DRUG INTERACTIONS:

- Current drug interaction databases should be consulted for more information.

ATC CODE:

Plerixafor L03AX16

REFERENCES:

1. Duarte et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant. 2011 46(1):52-8.
2. Micallef IN et al Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009;15(12):1578-1586.
3. Mozobil Summary of Product characteristics Accessed October 2018 Available at https://www.ema.europa.eu/documents/product-information/mozobil-epar-product-information_en.pdf

Version	Date	Amendment	Approved By
1	23/11/2018		Dr Kamal Fadalla

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

ⁱ ODMS – Oncology Drug Management System

CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at;

<http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/>

NCCP Regimen: Plerixafor and G-CSF	Published: 23/11/2018 Review: 23/11/2020	Version number: 1
Tumour Group: Leukaemia/BMT NCCP Regimen Code: 00536	IHS: Dr Kamal Fadalla	Page 3 of 3
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		